A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Phase 2
Completed
- Conditions
- Metastatic Breast Cancer ( HER2 Negative)Locally Recurrent
- Interventions
- First Posted Date
- 2010-12-29
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01268150
- Locations
- πΊπΈ
Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States
πΊπΈAugusta Oncology Associates, Augusta, Georgia, United States
πΊπΈCentral Georgia Cancer Care, Macon, Georgia, United States
A Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01261156
- Locations
- π³π±
PRA International, Zuidlaren, Netherlands
A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01260155
- Locations
- πΊπΈ
Celerion, Phoenix, Arizona, United States
A PK/PD Study of Fospropofol Disodium Compared With Propofol Injectable Emulsion
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01260142
- Locations
- πΊπΈ
Duke University Medical Center, Durham, North Carolina, United States
Single and Multiple Dose Asian Bridging Study
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01251731
- Locations
- πΊπΈ
Parexel International, Early Phase Clinical Unit, Los Angeles, California, United States
Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT01241669
- Locations
- πΊπΈ
Quintiles Phase I Services, Overland Park, Kansas, United States
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT01240421
A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01240187
- Locations
- π¬π§
Quotient Clinical, Edinburgh, United Kingdom
E7080 Food Effect Study in Healthy Subjects
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- Drug: HOPE
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01240408
- Locations
- πΊπΈ
Charles River Clinical Studies, NW, Tacoma, Washington, United States
A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: Active Comparator BDrug: Placebo Comparator BDrug: Placebo Comparator A
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT01230853
Β© Copyright 2025. All Rights Reserved by MedPath